Trinity Biotech
TRIB
23 hedge funds and large institutions have $2.3M invested in Trinity Biotech in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 5 closing their positions.
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
21% more funds holding
Funds holding: 19 → 23 (+4)
0.46% less ownership
Funds ownership: 1.18% → 0.72% (-0.46%)
22% less capital invested
Capital invested by funds: $2.95M → $2.3M (-$646K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
+$25.1K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$23.6K |
| 3 |
GI
GAMMA Investing
Foster City,
California
|
+$17.8K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$16.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$14.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$81.7K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$46K |
| 3 |
HF
HRT Financial
New York
|
-$37K |
| 4 |
VF
Virtu Financial
New York
|
-$20K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$15.6K |
TRIB Hedge Fund Activity: Q4 2024 in Review
23 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q4 2024, worth a combined $2.3M — down 22% from $2.95M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new TRIB positions and 5 closed out — a net gain of 4 holders — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Hunter Associates Investment Management, adding an estimated $25.1K. The largest seller was Renaissance Technologies, cutting an estimated $81.7K.
- 23 institutional investors held Trinity Biotech (TRIB) as of Q4 2024, up from 19 in Q3 2024.
- Funds reported $2.3M of Trinity Biotech stock for Q4 2024, down 22% quarter-over-quarter.
- 9 funds opened new Trinity Biotech positions in Q4 2024 and 5 closed out, a net change of +4 holders.
- The largest Trinity Biotech buyer in Q4 2024 was Hunter Associates Investment Management, an estimated $25.1K added.
- The largest Trinity Biotech seller in Q4 2024 was Renaissance Technologies, an estimated $81.7K sold.
Based on aggregated 13F filings for Q4 2024.